Monarch Medical Technologies, the maker of EndoTool, a leading provider of inpatient glycemic management solutions, enthusiastically supports the Centers for Medicare and Medicaid Services’ (CMS) recent introduction of electronic clinical quality measures (eCQMs) for Severe Hypoglycemia and Severe Hyperglycemia. These measures will require mandatory reporting in CY 2026 reporting period, and impact reimbursement in FY 2028. Reducing patient harm through the monitoring and reporting of glycemic control aligns perfectly with Monarch’s mission to offer innovative, evidence-based tools that improve patient outcomes and optimize hospital workflows.

Charles Cornish, CEO of Monarch Medical Technologies, stated, “These CMS measures underscore the vital importance of specialized care for diabetes management in hospitals. Our EndoTool platform is fully equipped to support hospitals in meeting these new standards, ensuring that patient care is both safe and effective.”

Our platform is designed not only to ensure compliance with new CMS mandates but also to empower healthcare providers to deliver superior glycemic management. By leveraging real-time data and predictive analytics, EndoTool helps clinicians make informed decisions that significantly reduce the risks of hypoglycemia and hyperglycemia, which are common yet serious complications in hospitalized patients.

Dr. Paul Chidester, Chief Medical Officer of Monarch Medical Technologies, commented, “The implementation of these CMS mandates will undoubtedly enhance the quality of glycemic management delivered across the healthcare spectrum and reduce patient harm. At Monarch, we are committed to advancing clinical practices through technology that promotes safety and efficiency.”

The new CMS mandates are a crucial step forward in making diabetes care a national priority, ensuring transparency and accountability in healthcare institutions across the country. These measures will enable public reporting and benchmarking, which are essential for advancing the quality of care and addressing health disparities.

Joseph A. Aloi, MD Section Chief of Endocrinology and Metabolism at Wake Forest Baptist Health and Chair of the Clinical Advisory Board at Monarch Medical Technologies added, “This is a transformative moment for diabetes management. Mandatory reporting with an impact on reimbursement not only increases visibility but also drives advancements in treatment protocols and patient outcomes. EndoTool is at the forefront of these innovations, continuously improving patient care technologies in response to such significant policy changes.”

As our healthcare system continues to evolve, Monarch Medical Technologies remains dedicated to innovation and collaboration. We are proud to work alongside CMS, healthcare providers, and industry partners to enhance inpatient glycemic management protocols and drive meaningful improvements in patient safety and health outcomes.

We invite our partners and the healthcare community to join us in preparing for these new standards. For more information on how EndoTool can help your organization adapt to and excel under the new CMS mandates, please visit our website https://monarchmedtech.com.

For more information on the CMS reporting requirements for inpatient diabetes management, explore our blog CMS Changes for Inpatient Diabetes Management.